CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

UnitedHealth Group’s ( UNH) new CEO, Stephen Hemsley, is shaking up the senior management of the company, appointing Patrick Conway, newly named CEO of the managed care giant’s Optum unit, as the head ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...